GlassScriptPhysician profile
Paul M Kramer
NPI 1205843828
$1,164.34
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $965 · 2020: $176 · 2021: $23.08.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $188.99 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $174.30 | 2019-2020 | |
| Glaxosmithkline, LLC. | $163.73 | 2019-2020 | |
| Amgen INC. | $146.52 | 2019 | |
| Merck Sharp & Dohme LLC | $128.95 | 2019-2020 | |
| Allergan, INC. | $46.81 | 2019 | |
| Amarin Pharma, INC. | $38.82 | 2019-2020 | |
| Pfizer INC. | $38.11 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.15 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $33.98 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $28.29 | 2019 | |
| Lilly USA, LLC | $26.63 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.54 | 2019 | |
| Edwards Lifesciences Corporation | $24.30 | 2019 | |
| Esperion Therapeutics, INC. | $23.08 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $18.45 | 2019 | |
| Shire North American Group INC | $11.56 | 2019 | |
| Genentech USA, INC. | $11.13 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.